AEON Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AEON NYSE American 2836 www.aeonbiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AEON Biopharma, Inc.

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - Jun 4th, 2026 5:00 am
Cervical Dystonia Market to Witness Robust Growth During the Forecast Period (2026-2036) Driven by the Expanding Therapeutic Options | DelveInsight - Jun 2nd, 2026 8:01 am
Why You Might Be Interested In Aeon Co. (M) Bhd. (KLSE:AEON) For Its Upcoming Dividend - May 24th, 2026 6:02 pm
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 14th, 2026 2:05 pm
AEON Biopharma Sets Annual Shareholder Meeting - Apr 24th, 2026 2:05 pm
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - Apr 3rd, 2026 2:10 pm
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards - Apr 3rd, 2026 2:05 pm
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program - Mar 30th, 2026 2:05 pm
Aeon Biopharma announces FDA feedback after Type 2a meeting - Mar 26th, 2026 6:17 am
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program - Mar 25th, 2026 6:00 am
AEON Biopharma Appoints John Bencich as Chief Financial Officer - Mar 9th, 2026 2:05 pm
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting - Mar 5th, 2026 2:05 pm
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions - Jan 21st, 2026 2:05 pm
An Intrinsic Calculation For Aeon Co. (M) Bhd. (KLSE:AEON) Suggests It's 42% Undervalued - Jan 14th, 2026 12:37 am
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong - Dec 15th, 2025 2:05 pm
Investors in Aeon (M) Bhd (KLSE:AEON) have unfortunately lost 24% over the last year - Dec 14th, 2025 7:14 pm
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling - Nov 20th, 2025 6:30 am
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth - Nov 14th, 2025 6:30 am
AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis Data - Nov 13th, 2025 6:30 am
The Returns At Aeon (M) Bhd (KLSE:AEON) Aren't Growing - Oct 22nd, 2025 12:14 am